Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Juan C. Ramos, Joseph A. Sparano, Amy Chadburn, Erin G. Reid, Richard F. Ambinder, Eric R. Siegel, Page C. Moore, Paul G. Rubinstein, Christine M. Durand, Ethel Cesarman, David Aboulafia, Robert Baiocchi, Lee Ratner, Lawrence Kaplan, Adam A. Capoferri, Jeannette Y. Lee, Ronald Mitsuyasu, Ariela Noy

Blood (2020) 136 (11): 1284–1297.

https://doi.org/10.1182/blood.2019003959

Published: 2020

Includes: Supplemental data

Journal Articles

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Blood (2016) 128 (8): 1050–1058.

https://doi.org/10.1182/blood-2015-08-664706

Published: 2016

Journal Articles

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

Ariela Noy, Jeannette Y. Lee, Ethel Cesarman, Richard Ambinder, Robert Baiocchi, Erin Reid, Lee Ratner, Nina Wagner-Johnston, Lawrence Kaplan

Blood (2015) 126 (2): 160–166.

https://doi.org/10.1182/blood-2015-01-623900

Published: 2015

Includes: Supplemental data

Journal Articles

A Modified Dose Intensive R- CODOX-M/IVAC For HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL) Demonstrates High Cure Rates and Low Toxicity: Prospective Multicenter Phase II Trial Of The AIDS Malignancy Consortium (AMC 048)

Ariela Noy, MD, Lawrence Kaplan, MD, Jeannette Y Lee, Ph.D.

Blood (2013) 122 (21): 639.

https://doi.org/10.1182/blood.V122.21.639.639

Published: 2013

Journal Articles

Long-Term Outcomes in Patients with Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation (AlloSCT) for Relapse After Initial Autologous Bone Marrow Transplant (ASCT).

Mary-Elizabeth Percival, MD, Lloyd E. Damon, MD, Thomas Martin, MD, Lawrence Kaplan, MD, Weiyun Ai, MD PhD, Jeffrey L. Wolf, MD, Sanghee Hong, Charles Linker, MD, Curt A. Ries, MD, Charalambos Andreadis, MD MSCE

Blood (2009) 114 (22): 2299.

https://doi.org/10.1182/blood.V114.22.2299.2299

Published: 2009

Journal Articles

Feasibility and Toxicity of a Modified Dose Intensive R- CODOX-M/IVAC for HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL): Preliminary Results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC).

Ariela Noy, MD, Lawrence Kaplan, MD, Jeannette Lee

Blood (2009) 114 (22): 3673.

https://doi.org/10.1182/blood.V114.22.3673.3673

Published: 2009

Journal Articles

Tacrolimus, Mini-Methotrexate and Mycophenolate Mofetil Is Safe and Effective as Acute Gvhd Prophylaxis for Non-Myeloablative Unrelated Donor Allogeneic Stem Cell Transplantation.

Sanghee Hong, Thomas Martin, MD, Lloyd E. Damon, MD, Lawrence Kaplan, MD, Willis H. Navarro, MD, Charles Linker, MD

Blood (2009) 114 (22): 1172.

https://doi.org/10.1182/blood.V114.22.1172.1172

Published: 2009

Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

Blood (2007) 110 (11): 3427.

https://doi.org/10.1182/blood.V110.11.3427.3427

Published: 2007

Journal Articles

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, John Bender, PharmD

Blood (2007) 110 (11): 2567.

https://doi.org/10.1182/blood.V110.11.2567.2567

Published: 2007

Journal Articles

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Teresa Melink, NP, Song Liu, John Bender, PharmD

Blood (2006) 108 (11): 691.

https://doi.org/10.1182/blood.V108.11.691.691

Published: 2006

Journal Articles

Neither Germinal Center (GC) vs Non-Germinal Center (Non-GC) Phenotype nor FOXP1 Expression Correlate with Outcome in AIDS-Associated Diffuse Large B-Cell Lymphoma (DLBCL): Study of Patients from AIDS Malignancies Consortium Trials 010 and 034.

Amy Chadburn, MD, Xia Chen, MD PhD, April Chiu, MD, Elizabeth Hyjek, MD PhD, Wayne Tam, MD PhD, Lawrence Kaplan, MD, David T. Scadden, MD, Daniel M. Knowles, MD, Ethel Cesarman, MD PhD

Blood (2006) 108 (11): 2023.

https://doi.org/10.1182/blood.V108.11.2023.2023

Published: 2006

Journal Articles

Evidence for Disease Specific Immunophenotypic Abnormalities in Blood from Patients with Mantle Cell Lymphoma.

Amy B. Narvaez, BS, Ronnie L. Gascon, BS, Rongzhen Zhang, BS, Lawrence Kaplan, MD, Michael S. McGrath, MD, PhD

Blood (2005) 106 (11): 4684.

https://doi.org/10.1182/blood.V106.11.4684.4684

Published: 2005

Journal Articles

Phase I/II Study of Bortezomib in Combination with Liposomal Doxorubicin and Melphalan in Relapsed or Refractory Multiple Myeloma.

Ajai Chari, MD, Lawrence Kaplan, MD, Charles Linker, MD, Lloyd E. Damon, MD, Willis H. Navarro, MD, Thomas Martin, MD

Blood (2005) 106 (11): 5182.

https://doi.org/10.1182/blood.V106.11.5182.5182

Published: 2005

Journal Articles

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Omer Koc, MD, Charles Redfern, MD, Peter Wiernik, MD, Fred Rosenfelt, MD, Jane Winter, MD, Troy Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, PhD, Rene Castillo, MD, Nalini Janakiraman, MD, Dan Gold, PhD, John Gutheil, MD, John Bender, PharmD

Blood (2005) 106 (11): 772.

https://doi.org/10.1182/blood.V106.11.772.772

Published: 2005

Journal Articles

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, John F. Bender, PharmD

Blood (2004) 104 (11): 587.

https://doi.org/10.1182/blood.V104.11.587.587

Published: 2004

Journal Articles

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Blood (2004) 104 (11): 4640.

https://doi.org/10.1182/blood.V104.11.4640.4640

Published: 2004

NARROW

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma

A Modified Dose Intensive R- CODOX-M/IVAC For HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL) Demonstrates High Cure Rates and Low Toxicity: Prospective Multicenter Phase II Trial Of The AIDS Malignancy Consortium (AMC 048)

Long-Term Outcomes in Patients with Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation (AlloSCT) for Relapse After Initial Autologous Bone Marrow Transplant (ASCT).

Feasibility and Toxicity of a Modified Dose Intensive R- CODOX-M/IVAC for HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL): Preliminary Results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC).

Tacrolimus, Mini-Methotrexate and Mycophenolate Mofetil Is Safe and Effective as Acute Gvhd Prophylaxis for Non-Myeloablative Unrelated Donor Allogeneic Stem Cell Transplantation.

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH) Following Rituximab Induction in Patients (pts) with Follicular B-Cell Lymphoma (FL): Progression Free Survival (PFS) at 4-Year Follow Up.

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Neither Germinal Center (GC) vs Non-Germinal Center (Non-GC) Phenotype nor FOXP1 Expression Correlate with Outcome in AIDS-Associated Diffuse Large B-Cell Lymphoma (DLBCL): Study of Patients from AIDS Malignancies Consortium Trials 010 and 034.

Evidence for Disease Specific Immunophenotypic Abnormalities in Blood from Patients with Mantle Cell Lymphoma.

Phase I/II Study of Bortezomib in Combination with Liposomal Doxorubicin and Melphalan in Relapsed or Refractory Multiple Myeloma.

Extended Follow-Up and Analysis with Central Radiological Review of Patients Receiving FavId ® (Id/KLH) Vaccine Following Rituximab.

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only